Can a smartphone program and glucose monitor reduce heart risks after gestational diabetes?

NCT ID NCT06648174

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a lifestyle program delivered through a mobile app, combined with a continuous glucose monitor (Abbott FreeStyle Libre 2), can improve blood sugar control and reduce cardiometabolic risk in 120 pregnant women diagnosed with gestational diabetes. Participants wear the glucose monitor during pregnancy and receive personalized feedback. The goal is to see if this approach leads to better health outcomes for both mother and baby.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Continuous glucose monitor (Abbott FreeStyle Libre 2) and a lifestyle intervention based on the health belief model, delivered via mobile health
What this could lead to
If successful, this approach could help women with gestational diabetes better control their blood sugar and reduce long-term heart and metabolic risks.
What could go wrong
This is a small, early-stage study (120 participants) testing a behavioral intervention, so results may not apply broadly. The lifestyle program requires active participation, and the glucose monitor may cause skin irritation in some users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTINUOUS GLUCOSE MONITORING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Taiwan University Hospital Hsin-Chu Branch BioMedical Park Hospital

    RECRUITING

    Hsinchu, 302058, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.